GLP-1 Reshapes APAC Consumption: The End of the "Easy Yes" Era

Overview

Based on proprietary survey data from 533 current GLP-1 users in China, India, and Korea, this report argues that the impact of GLP-1 drugs on the Asia-Pacific consumer sector extends far beyond simply "eating less," fundamentally dismantling the "easy yes" mechanism that underpinned decade-long Asian consumption growth. The report constructs an analytical framework tracing the chain from desire triggers to convenience-driven conversion and repeat purchase. It posits that when appetite and impulse diminish, transactions may no longer occur even if convenience remains unchanged. Consequently, covered names are categorized into three groups: high-risk firms reliant on the "easy yes" model, those adapting through transformation, and beneficiaries serving "goal-oriented" spending. The report warns that valuation repricing may precede actual earnings shocks.

Core views

The consumption contraction triggered by GLP-1 exhibits cross-category and cross-market behavioral consistency. Despite significant differences in dietary structures, channel ecosystems, and social norms among China, India, and Korea, user behavior is highly convergent: approximately 75% reduced intake of indulgent foods, 62% reduced alcohol consumption, nearly 70% of tobacco users smoked less, 74% reduced takeout orders, and 84% reported a marked decline in the desire to "treat themselves" or buy impulsively. This contraction extends beyond calorie-related categories to encompass all consumption scenarios relying on the chain of "desire trigger → convenience conversion → social permission → repeat purchase." The report identifies a deeper mechanism: GLP-1 weakens consumers' tendency to say "Yes" without thought before decision-making, posing systemic challenges to business models dependent on low-threshold conversion. The nature of consumption risk is evolving from "smaller basket" to "disappearing transactions." The report distinguishes three tiers of risk: basket risk (buying less but still buying), frequency risk (reduced purchase frequency), and occasion risk (the entire consumption scenario ceasing to exist). For enterprises relying on high frequency, low basket size, and habitual repurchase (e.g., fast food, delivery platforms, snacks/beverages), frequency risk directly attacks customer lifetime value, store utilization, and operating leverage. In social dining, holiday celebrations, and similar contexts, user restraint not only affects individual consumption but creates multiplier effects by reducing shared dishes and beverages, leading to overall table collapse. Traditional responses to basket risk such as price hikes, portion adjustments, or new product launches may prove ineffective against the disappearance of occasions. "The Wallet Follows Goals": Spending is being reallocated from indulgence to control and visible progress types. While impulse spending is suppressed, users are not stopping expenditure entirely; they are redirecting budgets toward categories that help manage weight loss progress, maintain results, or visualize outcomes. Surveys show 62% increased gym spending, 58% increased protein/supplement consumption, and 51% increased medical checkup expenses, with selective increases in athletic apparel and beauty treatments. Conversely, traditional discretionary categories like jewelry, luxury goods, perfumes, and electronics have not seen widespread growth. This indicates that current consumption upgrades represent "purposeful reallocation" rather than broad wealth effects. Only brands providing a "sense of control" and "visible progress" can secure new consumption rationales in the GLP-1 era. Valuation debates may precede earnings impacts. Although GLP-1 penetration in the Asia-Pacific region remains low and insufficient to immediately impact listed company EPS, the high stickiness of user behavior (89% plan to continue use for 6-12 months, 71% have recommended to others, 79% expect partial habit retention even after stopping drugs) forms a self-reinforcing flywheel. Referencing U.S. experience (adult usage rising from ~3% in 2024 to 11% in 2026), penetration could surge rapidly once oral formulations launch or local generics receive approval. Therefore, market skepticism regarding companies reliant on the "easy yes" model may begin before negative impacts appear in financial statements. The report specifically highlights three potential catalysts: oral GLP-1 entering Asia, Chinese approval of the first domestically produced semaglutide, and consumer companies launching innovations tailored for GLP-1 users.

Analysis framework

The report employs a three-layer analytical framework: "Behavioral Mechanism → Commercial Transmission → Asset Mapping." First, it uses cross-country primary surveys to identify common behavioral change patterns among GLP-1 users, isolating cultural differences to extract the core consumption mechanism of "easy yes." Second, it decomposes this mechanism into four components—desire, convenience, permission, and repetition—to analyze how GLP-1 erodes each layer sequentially, classifying impacts into three tiers of commercial risk: basket, frequency, and occasion. Finally, it constructs a three-category asset map based on each company's reliance on the "easy yes" mechanism and its ability to pivot toward "goal-oriented" offerings. This approach transcends simple listing of category winners and losers, focusing instead on shifts in underlying consumption logic and their differential impacts on various business models, enabling investors to identify valuation fragility and resilience sources before earnings data materializes.

Methodology notes

• Event博弈 and Behavioral FinanceExpectation Gap / Expectation Management

  Valuation debate precedes EPS realization

  The report notes that for consumer stocks dependent on specific growth algorithms (e.g., high-frequency repurchase), markets often downgrade valuation multiples due to sustainability doubts before actual earnings decline. Although GLP-1's behavioral impact is not yet reflected in financial statements, signals regarding user stickiness and habit persistence are sufficient to trigger valuation re-rating, reminding investors to focus on expectation shifts rather than merely tracking current performance.

• Industry/Industrial Analysis Framework

  "Easy Yes" Consumption Transmission Chain

  The report innovatively attributes seemingly unrelated consumption categories (snacks, delivery, tobacco/alcohol, social dining) to a single behavioral mechanism: triggered by desire, converted via convenience, sanctioned by society, and monetized through repetition. GLP-1 reduces efficiency across the entire chain by weakening initial desire. This framework helps investors look beyond category appearances to identify portfolios truly exposed to the same underlying risk.

• Corporate Fundamentals and Financial Framework

  Three-Tier Consumption Risk Stratification (Basket/Frequency/Occasion)

  The report categorizes demand shocks from GLP-1 into three severity levels: basket risk (reduced quantity per transaction), frequency risk (reduced number of transactions), and occasion risk (complete disappearance of consumption scenarios). This stratification aids in assessing corporate room for maneuver—basket risks can be mitigated via product adjustments, whereas occasion risk implies the foundational business model is shaken, necessitating more fundamental transformation.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Mixue (蜜雪冰城)

  Typical "Easy Yes" Dependent: High frequency, low price, impulse-driven; vulnerable to frequency risk

  Weaknesses

  Heavily reliant on immediate desire triggers and low decision costs; lacks goal-oriented value anchors

  Comparison

  Shares the "Easy Yes" high-risk group with JUBI and Calbee, though Mixue has stronger frequency attributes

  Risks

  Valuation under pressure first; if users reduce store visit frequency, operating leverage deteriorates rapidly

• ITC

  Habit-driven Tobacco + FMCG Giant, attempting extension towards nutrition and control

  Strengths

  Diversified business provides buffer; already has health product line layout

  Weaknesses

  Core tobacco business faces reality of 69% users reducing intake

  Comparison

  More adaptable than pure impulse-dependent names, but transformation speed lags behind TATACONS

  Risks

  Tobacco revenue decline may outpace new business growth, dragging down overall valuation

• Haitian (海天味业)

  Beneficiary of Return to Home Cooking: Increased home cooking drives demand for condiments

  Strengths

  Products naturally fit "controlled intake" scenarios; high brand trust

  Comparison

  More benefited by transaction venue shift compared to takeout-dependent catering supply chains

  Risks

  If users shift to pre-packaged healthy meal kits instead of home cooking, benefit level is limited

• Asics (亚瑟士)

  Sports gear as vehicle for "visible progress"; 84% users increasing exercise drives professional demand

  Strengths

  Strong functional attributes, directly linked to weight loss goals; possesses foundation for repeat purchase

  Comparison

  More likely to be included in "health investment" budget compared to fashion athletic apparel

  Risks

  Market share may be lost if fitness craze fades or competitors strengthen functional marketing

• Wuliangye (五粮液)

  Premium Baijiu Representative; social banquets impacted by GLP-1 user restraint

  Strengths

  Gift and collection attributes provide some non-drinking demand support

  Weaknesses

  Core consumption scenarios (business/holiday gatherings) are precisely where behavioral inhibition is strongest

  Comparison

  More reliant on formal occasions than daily alcohols like beer, thus facing higher occasion risk

  Risks

  If social drinking culture weakens long-term, terminal sales will remain under pressure

Key data

• Percentage of GLP-1 Users Reporting Reduced Appetite85%Proportion of respondents in China, India, and Korea reporting significantly reduced appetite; 89% in China, 92% in Korea
• Percentage of Users Reducing Indulgent Food Intake~75%Includes snacks, fried foods, sugary drinks, etc.; specific categories vary by country but the direction is consistent
• Percentage of Users Reducing Alcohol Consumption62%Covers all drinkers, indicating impact extends beyond food categories
• Percentage of Users Reducing Takeout Orders74%Stands at 74% even in China, the global market with most convenient delivery services; simultaneously, 80% report cooking more at home
• Percentage of Users Reporting Decline in Impulse/Treat Yourself Desire84%Indicates consumption willingness itself is suppressed, not just volume reduction
• Percentage of Users Increasing Gym Spending62%Representative of "goal-oriented" spending; highest in India at 75%
• Percentage of Users Planning Continued GLP-1 Use for at Least 6-12 Months89%Reflects high retention intent, supporting expectations of sustained behavioral change
• Cumulative Adult GLP-1 Usage Rate in U.S. (as of 2026)15%Gallup data, used to parallel Asia-Pacific future penetration paths

Impact & implications

The report argues that the core impact of GLP-1 on the Asia-Pacific consumer sector lies in shaking the growth paradigm established over the past decade, which centered on "eliminating friction" and "capturing impulses." For companies reliant on high frequency, habits, and low-decision-cost models, even if short-term revenue does not slide, the growth persistence assumptions implied in their valuations face correction pressure. Conversely, companies capable of embedding products and services into the new narratives of "health management, visible progress, and self-control" stand to gain superior valuation duration. This shift requires investors to redefine the moat of consumer stocks: shifting from "reach efficiency" to "capacity to provide meaning." Furthermore, given the high stickiness and social diffusion of behavioral changes, the scope of impact may expand non-linearly with penetration rates, rendering traditional linear extrapolation methods for earnings projections ineffective.

Risks

• Oral GLP-1 drug approval in Asia occurs earlier than expected, accelerating penetration and behavioral diffusion
• China's domestic semaglutide batch launch in 2027 drastically lowers medication thresholds
• Consumer companies fail to timely launch new product formats adapted for GLP-1 users
• Valuations of entities relying on the "easy yes" model reflect pessimistic expectations too early
• Survey sample biased towards urban high-income groups; actual mass market behavioral changes may lag

What to watch

• Approval progress of oral Wegovy and Eli Lilly's orforglipron in China (expected late 2026 to early 2027)
• Approval and commercialization rhythm of China's local semaglutide biosimilars
• Whether APAC consumer companies introduce GLP-1 friendly products such as high-protein, small portions, and calorie-controlled options
• Whether quarterly same-store sales and user activity data for high-frequency consumption targets show abnormal declines
• Whether revenue growth rates for leaders in fitness, supplements, and aesthetics categories continue to outperform traditional discretionary consumption